Johnson & Johnson (NYSE: JNJ) is a Dividend King with 63 years of consecutive dividend increases, offering a 2.4% yield. The healthcare giant reported $94.2 billion in sales last year, with $26.2 billion in adjusted net earnings and roughly $19.7 billion in free cash flow. Johnson & Johnson expects sales to exceed $100 billion in 2026 and anticipates 6-8% earnings-per-share growth. The company’s strong balance sheet and acquisitions in medical technologies position it for continued success. Investors can expect a steadily rising payout from this healthy dividend stock.

Read more at Nasdaq: This 2.4%-Yielding Dividend King Remains As Healthy As Ever